Angiogenesis in cancer, vascular, rheumatoid and other disease

Nat Med. 1995 Jan;1(1):27-31. doi: 10.1038/nm0195-27.

Abstract

Recent discoveries of endogenous negative regulators of angiogenesis, thrombospondin, angiostatin and glioma-derived angiogenesis inhibitory factor, all associated with neovascularized tumours, suggest a new paradigm of tumorigenesis. It is now helpful to think of the switch to the angiogenic phenotype as a net balance of positive and negative regulators of blood vessel growth. The extent to which the negative regulators are decreased during this switch may dictate whether a primary tumour grows rapidly or slowly and whether metastases grow at all.

Publication types

  • Review

MeSH terms

  • Angiostatins
  • Animals
  • Arthritis, Rheumatoid / physiopathology
  • Endothelial Growth Factors / physiology
  • Eye / blood supply
  • Humans
  • Lymphokines / physiology
  • Mice
  • Neoplasm Metastasis*
  • Neoplasms / blood supply
  • Neovascularization, Pathologic*
  • Peptide Fragments / therapeutic use
  • Plasminogen / therapeutic use
  • Psoriasis / physiopathology
  • Time Factors
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Substances

  • Endothelial Growth Factors
  • Lymphokines
  • Peptide Fragments
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Angiostatins
  • Plasminogen